- Home
- OCS vs TSHA Comparison
OCS vs TSHA Comparison
Compare OCS & TSHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | OCS | TSHA |
|---|---|---|
| Founded | 2003 | 2019 |
| Country | Switzerland | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.5B |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | OCS | TSHA |
|---|---|---|
| Price | $28.40 | $4.51 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 9 |
| Target Price | ★ $39.57 | $10.56 |
| AVG Volume (30 Days) | 242.6K | ★ 2.7M |
| Earning Date | 03-10-2026 | 02-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $991,999.00 | ★ $6,310,000.00 |
| Revenue This Year | $14.53 | N/A |
| Revenue Next Year | $691.13 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $14.00 | $1.05 |
| 52 Week High | $28.01 | $6.02 |
Technical Indicators
Market Signals| Indicator | OCS | TSHA |
|---|---|---|
| Relative Strength Index (RSI) | 84.73 | 40.79 |
| Support Level | $26.13 | $4.50 |
| Resistance Level | $27.43 | $4.89 |
| Average True Range (ATR) | 1.38 | 0.31 |
| MACD | 0.43 | -0.05 |
| Stochastic Oscillator | 91.00 | 12.06 |
Price Performance
Historical ComparisonAbout OCS Oculis Holding AG Ordinary shares
Oculis Holding AG is a biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis.
About TSHA Taysha Gene Therapies Inc.
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes, TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.